Progress in human tumour immunology and immunotherapy
Progress in human tumour immunology and immunotherapy
复制标题
DOI：
10.1038/35077246
复制
发表时间：
2001-05-17
期刊：
影响因子：
64.8
通讯作者：
Rosenberg, SA
中科院分区：
文献类型：
--
作者：
Rosenberg, SA
对转移性黑色素瘤或肾癌患者应用白介素2的研究表明，免疫操作可以介导转移性癌症的持久消退。肿瘤抗原的分子鉴定为癌症患者开发有效的免疫疗法开辟了新的可能性。使用来自癌症抗原的多肽进行免疫的临床研究表明，携带癌症的患者可以提高具有抗肿瘤活性的高水平淋巴细胞。可以从免疫的患者身上分离出高度活跃的抗肿瘤淋巴细胞，并在体外培养，用于细胞转移治疗。目前的研究旨在了解癌症逃脱免疫攻击的机制。
Studies of the administration of interleukin-2 to patients with metastatic melanoma or kidney cancer have shown that immunological manipulations can mediate the durable regression of metastatic cancer. The molecular identification of cancer antigens has opened new possibilities for the development of effective immunotherapies for patients with cancer. Clinical studies using immunization with peptides derived from cancer antigens have shown that high levels of lymphocytes with anti-tumour activity can be raised in cancer-bearing patients. Highly avid anti-tumour lymphocytes can be isolated from immunized patients and grown in vitro for use in cell-transfer therapies. Current studies are aimed at understanding the mechanisms that enable the cancer to escape from immune attack.